Monika Davare

Oregon Health & Science University

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (7)

Clare Keddy

University of Minnesota

UNITED STATES

View details

Shannon McWeeney

Professor and Vice Chair

Oregon Health & Science University

UNITED STATES

View details

Michael Capra

Consultant Paediatric Oncologist, Clinical Professor - Trinity College Dublin

IRELAND

View details

Jeffrey Tyner

Assistant Professor

Oregon Health & Science University

UNITED STATES

View details

Kathreena M Kurian

University of Bristol

UNITED KINGDOM

View details

Jessica Boult

Institute of Cancer Research

UNITED KINGDOM

View details

David Kram

Associate Professor

University of North Carolina

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Monika Davare

Research Interests

Explore related searches

Contact this professor

Articles (10)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion

A Broccoli aptamer chimera yields a fluorescent K<sup>+</sup> sensor spanning physiological concentrations.

Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes.

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.

RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.

ROS1-dependent cancers - biology, diagnostics and therapeutics.

Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <i>ROS1</i> Fusions.

Collaborators (7)

Clare Keddy

Shannon McWeeney

Michael Capra

Jeffrey Tyner

Kathreena M Kurian

Jessica Boult

David Kram

Make your next move.